POR9: CLINICAL EPIDEMIOLOGY PRINCIPLES OF AND THE COST OF DRUG TRIALS  by Gorkov, V et al.
220 Abstracts
1Hôpital Lariboisière, Paris, France; 2Astra Hassle, Molndal, 
Sweden; 3University of California Los Angeles, Department of 
Medicine, Los Angeles, CA, USA; 4Mario Negri Institute, Milan, 
Italy; 5MAPI Research Institute, Lyon, France
OBJECTIVES: Quality of life (QoL) is being increasingly
used as a secondary endpoint in clinical trials. The accu-
rate and precise measurement of QoL requires rigorous
scientific attention to the design and validation of ques-
tionnaires. The aim of the present study is to review the
available regulatory and medical literature and to suggest
minimal standards for the validation of QoL instruments. 
METHODS: Existing FDA and EMEA guidelines were
reviewed. A Medline search strategy was developed to
identify and retrieve relevant publications. 
RESULTS: There are currently no regulatory guidelines
from either the FDA or EMEA regarding validation of
QoL instruments. The search strategy identified 238 arti-
cles on instrument validation and 22 review articles on
validation methodologies. There is consensus in the liter-
ature that QoL assessment must be formally validated in
order to be acceptable as scientific evidence of interven-
tion effectiveness. Minimal validation criteria include: 1)
a clear definition of QoL relevant to the studied popula-
tion, 2) documentation of scientific methods used to de-
velop questionnaire instrument(s), 3) demonstration of
the performance of the instrument(s) in terms of accept-
ability, validity, and responsiveness, and 4) documenta-
tion of statistical methods used to derive scales, domains,
and other constructs. 
CONCLUSIONS: A validation study should be performed
prior to incorporating QoL instruments into clinical trials.
Results of these studies should be published in the medical
literature. A validation checklist is proposed to assist regu-
latory bodies in evaluating the quality of QoL instruments
used to support regulatory applications.
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Pharmaceutical manufacturers are spending more than
10% of their annual gross income for research and devel-
opment. Pre-clinical studies take 20% of these expendi-
tures and clinical phases take 40%. But only 5% of the
substances that have passed the pre-clinical phase suc-
cessfully will pass the four clinical phases and be ap-
proved for usage. Such an outcome explains the low sen-
sitivity and selectivity of test-systems using the laboratory
animal as a model of human. These systems are based on
widespread theory of the phylogenetic species continuity
concept which propose that human and animals have the
same sensitivity to the therapeutic and toxic action of
drugs. The biochemical species stability concept is less
known and postulates the essential interspecies and in-
traspecies variability on a biochemical level. According to
this theory, human material (cell cultures and tissues)
should be used as a test-system for drug testing. Clinical
epidemiology is the new fast growth discipline which
gives evidence for using methods of therapy or diagnos-
tics. It has routine procedures for the quantitative estima-
tion of test-systems and characterizes them by sensitivity,
selectivity, and validity. These procedures allow to discard
low effective test-systems. Principles of clinical epidemiol-
ogy can increase successful trials and diminish costs.
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OBJECTIVE: The purpose of this research is to develop a
decision model for evaluating the impact of information
regarding alternative treatments, toxicity, efficacy, deliv-
ery method, and cost on demand for unique compounds. 
METHODS: This paper characterizes the relationship be-
tween multi-attribute utility theory and health-state prefer-
ences. Health outcomes arising from pharmaceutical in-
terventions are viewed as multiattribute commodities.
Presenters describe a method for reliable, utility-theoretic
quantification of health-state preferences. This procedure
requires estimating utility weights from stated-preference
(SP) data. Including health cost as an SP attribute facilitates
conversion of marginal utilities to marginal dollar values
to explicitly account for cost in determining market share.
Additionally, various utility specifications and simplifying
assumptions are described. Finally, a rule for simulating
aggregate choice behavior over time is presented. The pre-
diction rule employed draws upon random utility maximi-
zation with adaptive expectations. This method addresses
the probabilistic nature of the choice process by inclusion
of a residual term representing the effect of unobserved
factors on perceived utility. Expectation updating deals
with imperfect information about product attributes such
as efficacy and side effects by allowing learning to take
place over successive drug administrations. 
RESULTS: A numerical example considering migraine
medications demonstrates the capability of the decision
model. In this example, a general, preference-based form
for health-related utility facilitates direct estimation of
health attribute utility weights arising from pharmaceuti-
cal consumption. Manipulating pharmaceutical attributes
in a random utility framework simulates choice probabili-
ties. Repeatedly simulating choice probabilities with at-
tribute expectation updating provides market penetration
estimates for unique compounds over time. 
CONCLUSIONS: Combining stated preference survey
techniques with random utility and adaptive expectations
provides a unique and realistic method for predicting de-
mand for novel compounds.
